Last reviewed · How we verify
Experimental: V503
At a glance
| Generic name | Experimental: V503 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 3 |
Approved indications
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Headache
- Pyrexia
- Nausea
- Influenza
- Injection site pruritus
- Dizziness
- Nasopharyngitis
Key clinical trials
- A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (PHASE1)
- Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). (PHASE1)
- Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |